MatTek’s3DtissuemodelofthehumansmallintestineisourlatestinnovationadvancinginvitroGIresearchworldwide.Allowingforphysiologicalexposuresandhuman-relevantendpoints,EpiIntestinalisbeingincorporatedintopharmaceuticaldevelopmentprogramsacrosstheglobe.EpithelialPolarityHighlyDifferentiated,PhysiologicallyRelevantMultipleDonorsAvailableDeliveredReady-to-use&Easy-to-useTechnology: TissueCultureInsertTheEpiIntestinaltissuemodel(SMI-100)offersnumerousadvantagesversuscurrentlyavailablepreclinicaltestingmodelssuchasCaco-2.Thehumancell-based3Dmodelincorporatesenterocytes,panethcell,Mcells,tuftcellsandintestinalstemcellsintoahighlydifferentiated, polarizedepithelium.TheEpiIntestinalFTtissue(SMI-100-FT)includesanunderlyinglaminapropriacontainingnormalhumanintestinalfibroblastsandisusefultostudyinflammation,woundrepair,innateimmuneresponses,andfibrosis.Bothtissuesareculturedattheair-liquidinterface(ALI)toallowphysiological(luminal)exposureconditions.EpiIntestinalrecapitulates manyaspectsofnormalintestinalfunctionincluding barrier,metabolism,inflammatoryandtoxicityresponses,similartonativehumanintestinaltissue.ImportantfeaturesofEpiIntestinalincludethepresenceoffunctionaltightjunctionsandbrushbordersattheapicaltissuesurface. Invivo,brushbordersareindirectcontactwithluminalcontentsandincludeatleast22metabolicenzymesand19drugtransporters. EpiIntestinaltightjunctionsandbrushborderscloselymimichumanstructureandphysiology. Applications:TheEpiIntestinal3DhumantissuemodelisroutinelyutilizedforscreeningpharmaceuticalsforarangeofendpointsincludingGItoxicityandinflammation,drugmetabolism,drugpermeation,fibrosis,andintestinalinfection.Straightforwardprotocolsandtheevaluationofearlymolecularandcellularendpointsoftenallowscientiststoacquiredataindays,notweeksormonths.GIToxicityUseEpiIntestinalforahighlypredictiveassaytoevaluateGItoxicityofpharmaceuticals.GItoxicityreferenceInflammationandFibrosisUtilizeEpiIntestinal’shighlycontrolledinvitrocultureconditionstostudyintestinalinflammation,woundrepair,andfibrosis andassesstherapeuticeffects.IntestinalInflammationReferenceDrugDelivery&MetabolismUtilizeEpiIntestinalforhighlypredictiveandhuman-relevantdrugdelivery. AssessAPIbioavailABIlity(influx)andeffluxtransport,drugmetabolism,anddrug-druginteractions. EpiIntestinalcanbeco-culturedwithotherphysiologicalsystems(e.g.livercells)inmicrofluidicsystemstoexaminetheeffectofdrugmetabolitesonGItoxicityortopredictdrugpermeation/absorptionviathe“luminal”sideofthetissue.IntestinalDrugDeliveryReferenceWoundRepair/EpithelialRestitutionUseEpiIntestinalFTtobetterunderstandmechanismsofwoundhealinginthegutandtoevaluatetherapeuticeffects.IntestinalRestitutionReferenceIntestinalInfectionUtilizeEpiIntestinaltostudyGItractinfection,host-pathogeninteractions,andinnateimmuneresponses.BrowseourreferencelibrarytolearnmoreabouthowresearchershaveusedourEpiIntestinaltissueintheseareasofstudy. a[rel~="mtli_filesize96797kB"]:after {content:" (967.97 kB)"}a[rel~="mtli_filesize118MB"]:after {content:" (1.18 MB)"}TechSpecs:Tissue:Kit:SMI-100andSMI-100-FTEpiIntestinalkitsconsistof24individualtissues. SMI-196orSMI-196-FTEpiIntestinalkitsconsistof96tissuesinahighthroughputscreeningplate. Eachkit containstissues,culturemediumtosupportexperimentsfor24hours,andplasticware. PleasecontactMatTekforspecifickitcontents.Formats:SMI-100andSMI-100-FT: Individualtissuesculturedincellcultureinserts.Dimensions: 9mmtissuediameter(surfacearea=0.6cm2),underlyingmicroporousmembraneporesize= 0.4μmSMI-196andSMI-196-FT: Tissuesgrownin96-wellhighthroughputscreeningplate. Dimensions: 0.19cmtissuediameter(surfacearea=0.11cm2). Underlyingmicroporousmembraneporesize=0.4μmCulture:Air-liquidinterfaceLotnumbers:Tissuelotsproducedeachweekareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualsetsof24tissueswithinagivenproductionlotoftissues.Alltissuekitswithinaproductionlotareidenticalinregardstocells,medium,handling,cultureconditions,etc.Shipment:At4°Conmedium-supplemented,agarosegelsShipmentday:EveryMondayDelivery:TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Wednesday dependingonlocation.Shelflife:Includingtimeintransit,tissuesmaybestoredat4°Cforupto2dayspriortouse.However,thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat4°C(Wednesdaymorning).Lengthofexperiments:TissueculturescanbecontinuedforONE(1)MONTHormorewithgoodretentionofnormalmorphology.Tissuesmustbefedeveryotherdaywith5.0mlofmaintenancemedium(SMI-100-MM).Cellcultureinsertsareplacedatopwashers(EPI-WSHR)orculturestands(MEL-STND)in6-wellplatestoallowuseof5.0ml.Cells:Type:Primaryhumansmallintestinalepithelialcells(HSIE)Geneticmake-up:SingledonorDerivedfrom:HealthyadultdonorAlternatives:AlternatedonorsavailableuponrequestScreenedfor:HIV,Hepatitis-B,Hepatitis-C,mycoplasmaMedium:Basemedium:Dulbecco’sModifiedEagle’sMedium(DMEM)Growthfactors/hormones:EpidermalgrowthfactorandotherproprietaryfactorsAntibiotics:Gentamicin5µg/mlAnti-fungalagent:AmphotericinB0.25µg/mlpHIndicator:PhenolredOtheradditives:ProprietaryAlternatives:Phenolred-free,antibiotic-free,anti-fungal-freemediumandtissuesareavailable.Agentsareremovedatleast3dayspriortoshipment.QualityControlandSterility:Visualinspection:Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipmentSterility:Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontaminationScreeningforpathogens:AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“BiosafetyinmicroBIOLOGicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalserviceNotificationoflotfailure:IfatissuelotfailsQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutcharge.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossIBLe(Undernormalcircumstances,ET-50failureswillbenotifiedbyThursday5p.m.;sterilityfailureswillbenotifiedwithin8daysofshipment)
MatTek公司是麻省理工学院两个化学工程教授于1985成立的科技公司。1991年,该公司利用其核心的聚合物表面改性技术进入新兴的组织工程领域,目前已成长为的组织工程技术公司,致力于生产创新性的3D重构人体组织模型,该模型相较于传统2D细胞模型具有更可靠的实验结果。其生产的重构皮肤,眼部和呼吸道组织模型已广泛应用于化妆品,化工,医药和家用产品等行业的毒理学监控(OECD,欧盟的指导方针)及毒理学研究。
MatTek公司的基于人体细胞的3D皮肤模型EpiDerm于1993年研发上市,立即获得巨大的成功。从此MatTek通过以下方式彻底改变了基于人体细胞的体外模型市场:(1)低成本(降低50-80%的成本);(2)通过发表质量控制标准(同时具备阳性和阴性对照)以确保可为行业及监管机构接受的高可重复性水平;(3)优化研究人员的实验结果。通过创造性使用非动物的体外测试,融合降低(直接/间接)成本的强大协同效应及显著提高的产品质量,MatTek极大的降低产品成本、提高实验室效率及高质量的高可重复性产品,减少实验动物的使用,具有无可超越的长期组织可重复性;3-D仿真结构;高度分化的组织模型;代谢和分裂活性;源于正常的人体细胞;培养、操作简便;无血清培养;可定量的客观检测;物美价廉的优点。因而使得MatTek人细胞来源的体外组织模型被包括美国、加拿大、欧洲、日本和东亚的众多跨国公司与研究机构采用。
目前MatTek公司的产品主要包括EpiDerm(皮肤模型)、MelanoDerm(黑色素模型)、EpiOcular(眼周表皮模型)、EpiAirway呼吸道上皮模型)、EpiDermFT (全厚的皮肤模型) 、EpiVaginal(阴道上皮模型)、EpiOral(口腔上皮模型)、 EpiGingivalTM(牙龈上皮模型)、Psoriasis tissue(牛皮癣组织模型)及树突细胞。